SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
HKSE · 1873.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Viva Biotech Holdings’s quoted price sits in the lower half of its reported 52-week range, 56.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Viva Biotech Holdings’s forward annual dividend is HK$0.07 per share, paid quarterly. The forward yield is 5.44% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Viva Biotech Holdings’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Viva Biotech Holdings’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Apr 26, 2023 |
| -HK$0.26-143.66% vs estimate |
| HK$1.45B+32.52% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
HK$50.70+HK$0.05 (+0.1%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.37% below the high.
HK$44.48-HK$0.58 (-1.29%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.31% below the high.
HK$35.02-HK$2.68 (-7.11%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 29.2% below the high.
HK$38.30-HK$3.70 (-8.81%)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 52.51% below the high.
HK$1.49+HK$0.18 (+13.31%)
Frontage Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
HK$19.10-HK$0.31 (-1.6%)
Medtide Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.28% below the high.
